1. Introduction
===============

The central nervous system (CNS) is composed of two major classes of cells---neurons and glial cells---the latter of which can be subdivided into astrocytes, microglia and oligodendrocytes. While neurons provide the basis for signal transduction and information processing, glial cells account for a wide range of specific functions. Oligodendrocytes generate myelin sheaths surrounding axons, and they are therefore referred to as myelinating glial cells. Myelin sheaths are imperative for stabilization, protection, and electrical insulation of axons, which enables accelerated electrical signal propagation \[[@B1-ijms-16-15057],[@B2-ijms-16-15057],[@B3-ijms-16-15057]\]. This intimate interaction between axons and oligodendrocytes is highly vulnerable and can become functionally impaired or damaged upon traumatic CNS injury or in inflammatory demyelinating diseases, such as multiple sclerosis (MS). This disease features damage to myelin sheaths and oligodendrocytes owing to autoimmune- as well as neurodegenerative processes, leading to sustained myelin loss, impaired electrical signal transduction, and eventually axonal degeneration. MS is by far one of the most common demyelinating neuroinflammatory diseases, affecting approximately 2.5 million people worldwide \[[@B4-ijms-16-15057]\]. Its etiology is unknown, and both genetic and environmental factors are assumed to contribute to the pathogenesis \[[@B5-ijms-16-15057]\]. Due to the restricted capacity of the CNS to regenerate and repair damaged tissue, traumatic injuries or neurological diseases generally result in permanent damage, functional loss, and persisting disabilities. Interestingly, this diminished repair capacity not only relates to neurons and their axons, but also to mature and fully differentiated oligodendrocytes, which cannot compensate for myelin loss because they usually degenerate in diseased brain areas \[[@B6-ijms-16-15057],[@B7-ijms-16-15057]\].

However, demyelination can be counteracted to a certain extent via recruitment and activation of resident adult oligodendroglial precursor cells (OPCs) \[[@B8-ijms-16-15057]\]. These cells comprise 5%--8% of the total cell population in the adult human and rodent CNS throughout the gray and white matter \[[@B9-ijms-16-15057],[@B10-ijms-16-15057],[@B11-ijms-16-15057],[@B12-ijms-16-15057]\], and they can be identified by the expression of markers such as neural/glial antigen 2 (NG2) and platelet-derived growth factor receptor α \[[@B13-ijms-16-15057],[@B14-ijms-16-15057]\]. Similar to perinatal OPCs, this fraction of adult OPCs also expresses transcription factors such as Nkx2.2, Ascl1/Mash1, Olig2, and MyT1 under physiological and pathological conditions \[[@B15-ijms-16-15057],[@B16-ijms-16-15057],[@B17-ijms-16-15057],[@B18-ijms-16-15057],[@B19-ijms-16-15057],[@B20-ijms-16-15057],[@B21-ijms-16-15057]\]. Remyelination-related processes such as activation, recruitment, and differentiation \[[@B22-ijms-16-15057],[@B23-ijms-16-15057]\] are tightly regulated by a number of extrinsic and intrinsic factors that act either as inhibitors or activators \[[@B24-ijms-16-15057],[@B25-ijms-16-15057]\]. Upon demyelination, OPCs switch from an essential inert state to a mitotically active phenotype, which is accompanied by the up-regulation of oligodendrogenic genes, such as *Olig1/2* and *Nkx2.2* \[[@B13-ijms-16-15057],[@B15-ijms-16-15057],[@B26-ijms-16-15057]\]. Following OPC recruitment, cellular differentiation comprises contact with the demyelinated axons and expression of myelin genes and proteins, as well as a process of wrapping around axons with subsequent compaction to generate myelin sheaths \[[@B22-ijms-16-15057],[@B27-ijms-16-15057]\].

Remyelination can be very effective in experimental *in vivo* models, such as those based on cuprizone-mediated demyelination or upon direct injection of toxins such as lysolecithin or ethidium bromide \[[@B28-ijms-16-15057]\]. Nevertheless, myelin repair in MS varies between patients, lesions, and disease stages, and the efficiency of this endogenous repair process remains generally low, thus contributing to permanent deficits and dysfunctions. To a certain extent this decline correlates with failure of OPCs to successfully generate new myelinating cells. Although the underlying reasons are not yet fully understood, several lines of evidence point to the presence of multiple differentiation inhibitors that specifically constrain the glial regeneration potential \[[@B25-ijms-16-15057],[@B29-ijms-16-15057],[@B30-ijms-16-15057],[@B31-ijms-16-15057]\]. To treat existing MS lesions and to support myelin repair therapeutically, it is therefore important to exploit features of the naturally occurring repair process and to identify rate-limiting factors and signals. The aim of this review article is to show the extent to which regulated subcellular protein distribution is involved in oligodendrogenesis, and how this could be used to devise new interventional strategies.

2. Intracellular Protein Shuttling---A Mechanism Involved in Neurodegenerative Diseases?
========================================================================================

Intracellular protein shuttling is essential for protein function and for functional and spatial diversity \[[@B32-ijms-16-15057]\] because transport to specific subcellular sites can determine access to specific substrates or interaction partners, and also allows incorporation into functional biological mechanisms/pathways. This transport is highly regulated and occurs through nuclear pore complexes (NPCs) that allow ions, small molecules, and proteins smaller than 40 kDa to cross the nuclear envelope \[[@B33-ijms-16-15057]\]. Larger proteins are actively shuttled by two opposing nucleocytoplasmic transport receptors termed karyopherins in a signal-mediated manner. Importins compose a family of 16 members, including α and β transportin, that are responsible for transport from the cytoplasm to the nucleus, whereas exportins comprise six family members, including Crm1/XPO/exportin1, which is involved in nuclear export \[[@B34-ijms-16-15057],[@B35-ijms-16-15057],[@B36-ijms-16-15057]\]. These transport receptors mediate both translocation processes by recognizing specific nuclear localization and export signals (NLSs and NESs, respectively) and thus directing the distribution of cargo proteins \[[@B37-ijms-16-15057],[@B38-ijms-16-15057]\].

Translocation through the NPC occurs after receptor-cargo complexes interact with NPC proteins, followed by interaction with Ras-related nuclear protein guanosine triphosphate (Ran-GTP) and subsequent cargo release to the dedicated subcellular compartment \[[@B39-ijms-16-15057]\]. The active protein import across the NPC is powered by a nucleocytoplasmic Ran-GTP gradient and requires the hydrolysis of two GTPs. Nuclear localized guanine-nucleotide exchange factors (GEFs) maintain an elevated nuclear Ran-GTP concentration because they catalyze the exchange of guanosine diphosphate GDP to GTP on Ran molecules. Upon binding of an importin receptor to a cargo protein with an NLS sequence, this receptor-cargo complex is directed towards the NPC and passes through. The cargo is released in the nucleus by the binding of Ran-GTP to the importin receptors and subsequent displacement of the cargo. The importin/Ran-GTP complex then diffuses back to the cytoplasm where GTPase-activating proteins (GAPs) hydrolyze GTP to GDP, which leads to the release of importins and thus the availability for new import processes. However, nuclear cargo proteins with an NES sequence can bind to a previously formed exportin (*i.e.*, chromosome region maintenance 1, CRM1; also referred to as exportin1 or Xpo1) and Ran-GTP complex, and this heterotrimeric complex can then diffuse through the NPC into the cytoplasm. On the cytoplasmic side, the cargo dissociates from the complex by means of GAP-mediated hydrolyzation of GTP to GDP. CRM1 and Ran-GDP then diffuse back to the nucleus where GEFs exchange GDP to GTP ([Figure 1](#ijms-16-15057-f001){ref-type="fig"}).

Because nuclear localization of proteins such as transcription factors is key to their function, and an adequate localization of signaling proteins close to their downstream targets can be imperative for many signal transduction pathways, unbalanced nucleocytoplasmic shuttling can result in their inactivation. Undesired gain-of-functions can thus cause a variety of cellular malfunctions related to signaling, metabolic or structural properties \[[@B40-ijms-16-15057]\]. Nucleocytoplasmic transport failure has in fact been implicated in several neurodegenerative diseases and conditions, such as amyotrophic lateral sclerosis (ALS) \[[@B41-ijms-16-15057],[@B42-ijms-16-15057],[@B43-ijms-16-15057]\], Alzheimer's disease \[[@B44-ijms-16-15057]\], Huntington's disease \[[@B45-ijms-16-15057]\], traumatic injury \[[@B46-ijms-16-15057]\], and MS \[[@B47-ijms-16-15057],[@B48-ijms-16-15057]\]. For most of these disorders, neurodegeneration and axonal damage correlate with mislocation of proteins, such as histone-1 and β-catenin in the anterior horn cells of mutant Cu/Zn-superoxide dismutase (G93A) transgenic mice, an animal model for ALS, or in hippocampal neurons in Alzheimer's disease, revealing cytoplasmic accumulation of the nuclear transport factor 2 \[[@B42-ijms-16-15057],[@B44-ijms-16-15057]\]. In demyelinating diseases such as MS, particularly in the context of previously discussed endogenous repair activities, cells of the glial lineage are of primary interest. They have also been shown to be affected by impaired/dysregulated nucleocytoplasmic translocation, which will be presented in the next section in detail.

![Nuclear import of cargo proteins implicates the recognition of a nuclear localization sequence (NLS) by importin receptors. In the nucleus, importins are dissociated from the cargo through the binding of Ran-GTP. Nuclear guanine-nucleotide exchange factors (GEFs) maintain elevated nuclear Ran-GTP concentration levels. On the other hand, translocation to the cytoplasm is facilitated by a nuclear export sequence (NES), recognized by exportin receptors such as CRM1 and further interacting with Ran-GTP. Upon translocation of the export complex to the cytoplasm, the cargo dissociates from the complex by means of GTPase-activating proteins (GAP)-mediated hydrolyzation of Ran-GTP to Ran-GDP.](ijms-16-15057-g001){#ijms-16-15057-f001}

3. Nucleocytoplasmic Translocation Activities of Myelinating Glial Cells
========================================================================

Even though the restricted capacity of the CNS to regenerate myelin sheaths is linked to different regulatory factors/pathways, a broad range of regulators share common features. Not only do their expression and presence appear to limit glial maturation, but their subcellular localization within the oligodendroglial cells is assumed to constrain the regeneration process as well. Hence, precise and timely nucleocytoplasmic transport of these regulators across the nuclear membrane represents an essential mechanism for controlling their activity. For this reason, nuclear transport could be considered as a putative therapeutic target with potential implications for neurodegenerative diseases. This review therefore focuses on aberrant/dysregulated nucleocytoplasmic protein shuttling within oligodendroglial cells, its implication/contribution to the restricted capacity of the CNS to repair damaged tissue, and the description of possible molecular targets that could be used to develop therapeutic strategies.

3.1. Cell Cycle-Associated Proteins
-----------------------------------

In order to generate functional oligodendrocytes, cell cycle progression and differentiation must be tightly controlled. The shift between proliferation and differentiation depends on regulatory complexes involving cyclins, cyclin-dependent kinases (CDK), and cyclin-dependent kinase inhibitors (CDKIs) as well as phosphorylation-dephosphorylation events, all responding to intracellular and extracellular signals and influencing their expression levels and intracellular localization \[[@B49-ijms-16-15057]\]. Proliferating oligodendroglial cells feature elevated cyclin E and D; increased CDK2, -4, and -6 protein levels; and higher kinase activities of both CDK4/6-cyclin D and CDK2-cyclin E complexes as compared to cells permanently withdrawn from the cell cycle \[[@B50-ijms-16-15057]\]. In addition, Frederick and colleagues demonstrated that nuclear accumulation of cyclin D1 within OPCs is promoted upon fibroblast growth factor -2 and insulin-like growth factor-I stimulation \[[@B51-ijms-16-15057]\] and enhanced S-phase entry \[[@B52-ijms-16-15057]\].

Furthermore, nuclear activity of CDKs, especially of CDK2 maintaining the G1/S-phase checkpoint together with cyclin E, was shown to be necessary to retain cell cycle progression in mammals \[[@B53-ijms-16-15057]\]. Loss of CDK2, on the other hand, enhanced cell cycle exit and glial maturation, whereas active nuclear exclusion was found during the differentiation process in differentiating OPCs \[[@B54-ijms-16-15057],[@B55-ijms-16-15057]\] ([Figure 2](#ijms-16-15057-f002){ref-type="fig"}, [Table 1](#ijms-16-15057-t001){ref-type="table"}). Upon lysolecithin (LPC)-induced focal demyelination in adult mice, loss of CDK2 was shown to attenuate cell proliferation and to accelerate differentiation and remyelination \[[@B54-ijms-16-15057]\].

CDK5 absence led to nuclear translocation of the transcription factor FOXO1 and subsequently facilitated neuronal cell death \[[@B56-ijms-16-15057]\]; it also reduced myelin mRNA and myelination and delayed differentiation in oligodendroglial cells \[[@B57-ijms-16-15057]\]. Because retrograde intracellular transport depends on CDK5 activity \[[@B58-ijms-16-15057]\], loss of function and thus decreased OPC maturation have been proposed to largely reflect perturbed transport of mRNA, including that coding for myelin basic protein (MBP). Of note, intracellular transport of RNAs will be further described here in [Section 3.5](#sec3dot5-ijms-16-15057){ref-type="sec"}. Nuclear expression of CDK5 is increased following oligodendroglial differentiation \[[@B57-ijms-16-15057],[@B59-ijms-16-15057]\], and phosphorylation of the focal-adhesion-associated protein paxillin as well as of WASP family verprolin-homologous proteins WAVE1 and WAVE2 by CDK5 has been proposed to regulate OPC migration, differentiation, and myelination \[[@B59-ijms-16-15057],[@B60-ijms-16-15057],[@B61-ijms-16-15057]\]. This suggests that in oligodendroglial cells, CDK5's primary function appears to be the modulation of cellular differentiation rather than cell division ([Table 1](#ijms-16-15057-t001){ref-type="table"}).

E2F1, a member of the E2F family of transcription factors, plays a critical role in coordinating early cell cycle progression; in its unbound state, it directs the transcription of genes required for entry into the S phase \[[@B62-ijms-16-15057]\]. Unbound nuclear E2F1 is dependent on the phosphorylation state of retinoblastoma protein Rb, which sequesters E2F1 in its unphosphorylated state \[[@B63-ijms-16-15057]\]. However, increased Rb phosphorylation resulting from up-regulated CDK/Cyclin complexes leads to E2F1 release \[[@B64-ijms-16-15057]\], and recent studies revealed that OPC differentiation *in vitro* and *in vivo* is accompanied by nuclear export of E2F1 \[[@B65-ijms-16-15057]\]. E2F1 was identified as a key transcription factor modulating the expression of chromatin components in OPCs during the transition from proliferation to differentiation. Its nucleocytoplasmic shuttling was suggested to be required to dampen the E2F1-driven pattern of expression, thus allowing OPC differentiation to occur ([Table 1](#ijms-16-15057-t001){ref-type="table"}).

![(**A**) In early stages of oligodendroglial precursor cell (OPC) differentiation p57kip2 is predominantly located in nuclei. Kinase binding partners such as LIM Domain Kinase 1 (LIMK-1) and CDK2 appear to colocalize with p57kip2. Nuclear presence of CDK2 results in maintenance of cell cycle progression, while nuclear LIMK-1 is unable to inhibit cytoplasmic cofilin, a negative regulator of actin filament turnover. As a result actin depolymerization is enhanced. Moreover, interactions of p57kip2 with the transcription factors Ascl1/Mash1 and Hes5 appear to control target gene transcription. Upon p57kip2 binding Ascl1/Mash1's transcriptional activity was found to be blocked while Hes5 nuclear accumulation appears to be enforced by p57kip2 where it is supposed to interfere with myelin gene expression; (**B**) Mature oligodendroglial cells exhibit high cytoplasmic levels of p57kip2. Nuclear export of p57kip2 leads to dissociation from its binding partner Ascl1/Mash1 and results in myelin gene activation by this transcription factor. Furthermore, CDK2 and Hes5 translocate from the nucleus to the cytoplasm along with p57kip2 and are thus rendered functionally inactive. In addition, enhanced cytoplasmic levels of LIMK-1 can affect actin filament turnover. Cytoplasmic LIMK-1 is phosphorylating cofilin, which in turn interferes with its capacity to depolymerize actin filaments. Subsequently, this process of cytoplasmic trapping of inhibitory components by the p57kip2 protein, allows terminal differentiation to proceed.](ijms-16-15057-g002){#ijms-16-15057-f002}

CDKIs negatively regulate cell cycle progression by binding and inactivating cyclin/CDK complexes. Based on their CDK binding specificity, CDKI proteins fall into two subfamilies-namely, the inhibitor of kinase 4 (INK4) family and the CDK interacting protein/kinase inhibitory protein (Cip/Kip) family \[[@B66-ijms-16-15057]\]. The INK4 family includes p16INK4a, p15INK4b, p18INK4c, and p19INK4d, all of which competitively bind to CDK4 and CDK6 and prevent complex formation with cyclin D and block G1/S-phase transition. Cip/Kip family members comprise p21cip1, p27kip1, and p57kip2 interacting with CDK2, -4 and -6 \[[@B66-ijms-16-15057],[@B67-ijms-16-15057]\] ([Table 1](#ijms-16-15057-t001){ref-type="table"}). p27kip1 and p21cip1 were demonstrated to be important regulators of OPC proliferation and differentiation initiation because their nuclear expression increased during differentiation or during reversible cell cycle arrest in G1 caused by neuronal signals \[[@B68-ijms-16-15057],[@B69-ijms-16-15057]\]. Altered subcellular localization of p27Kip1 was shown to act as an intrinsic timer for oligodendroglial development that was found to progressively increase during rodent optic nerve development in a time-dependent manner as well as in purified OPC cultures \[[@B70-ijms-16-15057],[@B71-ijms-16-15057]\]. Overexpression and subsequent nuclear accumulation of p27kip1 were then shown to terminate proliferation, enhance MBP expression, and promote terminal differentiation \[[@B72-ijms-16-15057],[@B73-ijms-16-15057],[@B74-ijms-16-15057]\]. Likewise upon CNS injury, mitogen signals induced p27kip1 phosphorylation on serine-10, leading to CRM1-mediated nuclear export that facilitated cell cycle progression, especially in microglia and astrocytes \[[@B75-ijms-16-15057]\]. Upon LPC-induced demyelination, loss of p27kip1 also increased the proliferative response of OPCs to injury \[[@B76-ijms-16-15057]\].

In proliferating OPCs, the expression of the tumor suppressor p53 is low, and the protein is likely not functional based on its cytoplasmic localization \[[@B77-ijms-16-15057]\]. Translocation to the nucleus occurs upon mitogen removal, and p53 is then involved in the onset of OPC differentiation by stimulating p21cip1 expression, followed by the inhibition of CDK2-cyclin E complexes \[[@B77-ijms-16-15057]\]. Similarly, overexpression and nuclear accumulation of p18INK4c have also been shown to prevent OPC proliferation and to accelerate differentiation onset \[[@B78-ijms-16-15057],[@B79-ijms-16-15057]\]. However, *in situ* analysis of active MS lesions revealed increased expression of p53 in apoptotic oligodendrocytes suggesting it to be a critical pro-apoptotic effector \[[@B80-ijms-16-15057]\]. Accumulation of p53 resulted in up-regulation of death receptors, the ligands of which are present in the inflammatory milieu of active MS lesions ([Table 1](#ijms-16-15057-t001){ref-type="table"}).

As opposed to the general view of Cip/Kip proteins functioning exclusively as inhibitors of cyclin/CDK activities, increasing evidence suggests that they exert additional cellular functions outside the nucleus, such as regulation of cellular processes \[[@B81-ijms-16-15057],[@B82-ijms-16-15057]\]. In this regard, we demonstrated that the cyclin-dependent inhibitor p57kip2 negatively affects myelinating glial cell differentiation in the peripheral and central nervous system and that it controls glial fate decision by adult neural stem cells \[[@B55-ijms-16-15057],[@B83-ijms-16-15057],[@B84-ijms-16-15057],[@B85-ijms-16-15057]\]. Despite Cip/Kip family members being highly homologous in their N-terminal CDK-binding and C-terminal domains, p57kip2 features a large central proline-rich region distinct from all other CDKIs that possibly has unique functions not shared by p21cip1 and p27kip2 \[[@B86-ijms-16-15057],[@B87-ijms-16-15057]\]. This proline-rich region allows p57kip2 to bind LIMK-1. The nuclear presence of p57kip2 therefore prevents LIMK-1 from phosphorylating cytoplasmic cofilin and thus favors actin filament destabilization and disassembly \[[@B88-ijms-16-15057],[@B89-ijms-16-15057]\]. The p57kip2 protein, however, translocates spontaneously in differentiation-competent OPCs, and this subcellular translocalization process is key to its inhibitory role \[[@B55-ijms-16-15057]\]---that is, promoting myelin expression, higher morphological phenotypes, and enhanced myelination *in vitro* ([Figure 2](#ijms-16-15057-f002){ref-type="fig"}). In a recent study of established MS lesions, no evidence of a p57kip2 translocation in white matter OPCs could be found, suggesting a functional implication, in that prevented or slowed myelin repair could suffer from averted p57kip2 export \[[@B90-ijms-16-15057]\].

ijms-16-15057-t001_Table 1

###### 

Cell cycle-associated key molecules.

  Molecules   Major Function in OPCs                                                                   Role in MS/MS-Models                                             References
  ----------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CDK5        migration, differentiation and myelination, mRNA transport                               --                                                               Miyamoto *et al.*, 2007/2008 \[[@B59-ijms-16-15057],[@B60-ijms-16-15057]\]; Yang *et al.*, 2013 \[[@B57-ijms-16-15057]\]; Zhou *et al.*, 2015 \[[@B56-ijms-16-15057]\]
  CDK2        cell cycle progression                                                                   LPC: alters adult OPCs renewal, differentiation, remyelination   Malumbres *et al.*, 2005 \[[@B53-ijms-16-15057]\]; Caillava *et al.*, 2011 \[[@B49-ijms-16-15057]\]; Göttle *et al.*, 2015 \[[@B55-ijms-16-15057]\]
  E2F1        modulates chromatin components during transition from proliferation to differentiation   --                                                               Magri *et al.*, 2014 \[[@B65-ijms-16-15057]\]
  p21cip1     proliferation, differentiation                                                           --                                                               Ghiani *et al.*, 1999 \[[@B50-ijms-16-15057]\]
  p53         proliferation, differentiation                                                           MS lesions: apoptosis                                            Eizenberg *et al.*, 1996 \[[@B77-ijms-16-15057]\]; Wosik *et al.*, 2003 \[[@B80-ijms-16-15057]\]
  p27kip1     proliferation                                                                            LPC: proliferative response                                      Crockett *et al.*, 2005 \[[@B76-ijms-16-15057]\]; Raff *et al.*, 2007 \[[@B70-ijms-16-15057]\]; Durand *et al.*, 1997/1998 \[[@B71-ijms-16-15057],[@B74-ijms-16-15057]\]; Miskimis *et al.*, 2002 \[[@B72-ijms-16-15057]\]; Tamaki *et al.*, 2004 \[[@B73-ijms-16-15057]\]
  p57kip2     glial fate decision, differentiation                                                     MS lesions: myelin repair                                        Kremer *et al.*, 2009 \[[@B85-ijms-16-15057]\]; Jadasz *et al.*, 2012 \[[@B84-ijms-16-15057]\]; Pfeifenbring *et al.*, 2013 \[[@B90-ijms-16-15057]\]; Göttle *et al.*, 2015 \[[@B55-ijms-16-15057]\]

Abbreviations: lysolecithin (LPC), oligodendroglial precursor cells (OPCs), Multiple Sclerosis (MS).

3.2. Transcriptional Regulators
-------------------------------

Oligodendroglial lineage transcription factors Olig1 and Olig2 are basic helix-loop-helix (bHLH) proteins and important positive regulators of OPC differentiation \[[@B91-ijms-16-15057]\] ([Table 2](#ijms-16-15057-t002){ref-type="table"}). Their expression is induced by the secreted protein sonic hedgehog (Shh) during CNS development \[[@B92-ijms-16-15057]\]. Signaling through the canonical Gli pathway by binding of Shh to the Ptchd1 receptor stops the inhibition of the transmembrane protein Smoothened and allows the transcriptional activators Gli2/3 to translocate into the nucleus, where they induce the expression of Shh-target genes \[[@B93-ijms-16-15057]\]. Olig1/2 expression is required for both lineage determination and differentiation to proceed \[[@B94-ijms-16-15057],[@B95-ijms-16-15057]\], as shown by Olig1/2-deficient mice failing to develop progenitor cells \[[@B95-ijms-16-15057],[@B96-ijms-16-15057]\]. Interestingly, although both proteins are localized in the nucleus during development, they exhibit different localization patterns in the adult. While Olig2 remains in the nucleus, Olig1 is transferred to the cytoplasm in mature oligodendrocytes \[[@B17-ijms-16-15057]\]. Apart from facilitating myelin gene expression \[[@B97-ijms-16-15057],[@B98-ijms-16-15057]\], Olig1 appears to have a second function; upon phosphorylation of serine 138, it translocates to the cytoplasm and promotes membrane expansion and maturation of oligodendrocytes \[[@B99-ijms-16-15057],[@B100-ijms-16-15057]\]. In a cuprizone-mediated demyelination model and MS patient tissues, however, Olig1 relocated to the oligodendroglial nucleus, which suggested that it promotes the remyelination process \[[@B17-ijms-16-15057],[@B101-ijms-16-15057],[@B102-ijms-16-15057]\]. Similarly, when neural stem cells (NSCs) generated GFAP-positive astrocytes in culture, Olig2 disappeared from the nucleus and appeared in the cytoplasm \[[@B103-ijms-16-15057]\], raising the possibility that the nucleocytoplasmic translocation of Olig2 might be involved in astrogenesis \[[@B104-ijms-16-15057]\]. This possibility is further supported by Olig2 translocation mediating brain injury-induced differentiation of NG2-positive progenitor cell to GFAP-positive astrocytes in the adult \[[@B105-ijms-16-15057]\].

The achaete-scute complex homolog 1 (Ascl1/Mash1) protein encodes another transcriptional regulator important for oligodendroglial specification, differentiation, and myelination \[[@B106-ijms-16-15057],[@B107-ijms-16-15057],[@B108-ijms-16-15057]\] ([Table 2](#ijms-16-15057-t002){ref-type="table"}). Ascl1/Mash1 operates in genetic interactions with Olig2 during OPC specification, and loss of Mash1 function affects oligodendrogenesis. Ascl1/Mash1 activity is also required for proper differentiation into oligodendrocytes as it is known to regulate MBP promoter activity \[[@B108-ijms-16-15057],[@B109-ijms-16-15057]\]. During remyelination, both upon LPC-induced demyelination of the corpus callosum as well as in MS lesions, Ascl1/Mash1 activity was up-regulated along with increased oligodendrogenesis \[[@B108-ijms-16-15057]\]. A direct physical interaction with the p57kip2 protein occurs, and as a consequence of this binding, Ascl1/Mash1 transactivation properties are reduced. However, upon cytoplasmic translocation of p57kip2, Ascl1/Mash1 remains nuclear and can exert its full gene regulatory potential \[[@B55-ijms-16-15057]\] ([Figure 2](#ijms-16-15057-f002){ref-type="fig"}). This binding behavior differs from LIMK-1 and CDK2 and suggests multiple signaling pathways control complex assembly and disassembly around p57kip2.

The zinc-finger myelin transcription factor 1 (Myt1) is a DNA-binding protein that regulates proteolipid (PLP) transcription. \[[@B19-ijms-16-15057]\]. Interestingly, its nuclear accumulation was shown to be primarily required for OPC maturation because dominant negative Myt1 blocked OPC maturation and slightly inhibited proliferation \[[@B19-ijms-16-15057],[@B110-ijms-16-15057]\]. In OPCs Myt1 accumulated in the nucleus and continued to be expressed in cells transcribing PLP, whereas in mature oligodendrocytes it was restricted to the cytoplasm \[[@B111-ijms-16-15057]\]. Myt1 was suggested to play a role in oligodendroglial precursor cell responses to demyelination. Myt1 is localized in nuclei of OPCs in MS lesions and increased numbers of Myt1 positive OPCs were observed following murine hepatitis virus strain A59 (MHV) induced de- and remyelination \[[@B19-ijms-16-15057]\].

Inhibitor of differentiation (Id) proteins are non-DNA-binding transcriptional regulators, located downstream of the BMP signaling, that exert strong inhibitory effects on oligodendroglial differentiation. Nuclear accumulation of Id2 and Id4 results in complex formation with Olig1, Olig2, or Ascl1/Mash1 proteins for subsequent sequestration \[[@B112-ijms-16-15057],[@B113-ijms-16-15057]\]. These proteins translocate to the cytoplasm when spontaneous OPC differentiation proceeds, probably as a result of mitogen deprivation \[[@B114-ijms-16-15057]\], whereas Id2 and Id4 overexpression dominantly blocks myelin gene expression \[[@B109-ijms-16-15057]\].

In 2009 the G-protein coupled receptor 17 (GPR17) was found to be transiently expressed during oligodendrogenesis and to interfere with oligodendroglial differentiation via Id2 \[[@B113-ijms-16-15057],[@B115-ijms-16-15057]\] ([Table 2](#ijms-16-15057-t002){ref-type="table"}). In pathophysiological settings, such as MS or MOG~35--55~ induced experimental autoimmune encephalomyelitis (EAE), GPR17 appears to be up-regulated \[[@B113-ijms-16-15057]\], and its overexpression in mice or cultured OPCs has been shown to inhibit the oligodendroglial maturation by enforcing nuclear localization of Id2/4 \[[@B113-ijms-16-15057]\].

The nuclear presence of members of the Wnt/β-catenin signaling cascade in MS lesions, as well as recent observations on inhibited myelination and differentiation of oligodendrocytes following constitutive expression of β-catenin, suggests an active role regarding remyelination failure \[[@B116-ijms-16-15057],[@B117-ijms-16-15057],[@B118-ijms-16-15057]\]. Upon binding of Wnt to the transmembrane receptor Frizzled (FZD) in complex with the co-receptor low-density lipoprotein receptor-related protein (LRP), the cytoplasmic protein Disheveled (Dsh) was activated, preventing proteosomal degradation of β-catenin via inhibition of the glycogen synthase kinase 3-β (GSK3β) \[[@B119-ijms-16-15057],[@B120-ijms-16-15057]\]. In this context, pharmacological inhibition of GSK3β was demonstrated to promote nuclear translocation of β-catenin *in vivo* \[[@B121-ijms-16-15057]\]. Stabilized β-catenin translocates into the nucleus and subsequently interacts with transcription factors. One such factor is T-cell factor/lymphocyte enhancer factor 4 (Tcf4/Lef), with which β-catenin forms a complex that has been found to impair development of oligodendrocytes by repressing Olig2 expression \[[@B117-ijms-16-15057],[@B122-ijms-16-15057],[@B123-ijms-16-15057]\]. In human brains Tcf4 protein was expressed during development and in early MS lesions, where it colocalized with Olig2 in oligodendrocyte lineage cells \[[@B117-ijms-16-15057],[@B118-ijms-16-15057]\]. Interestingly, prevention of β-catenin translocation to the nucleus was demonstrated to promote remyelination and myelination \[[@B124-ijms-16-15057]\]. In the absence of β-catenin, TCF/LEFs assembled alternative complexes with alternate transcriptional co-repressors, such as Groucho/TLE or SMAD transcription factors \[[@B125-ijms-16-15057],[@B126-ijms-16-15057]\].

SMADs are downstream effectors of bone morphogenic proteins (BMPs), secreted proteins that form the largest subclass of the transforming growth factor-β (TGFβ) superfamily and participate in multiple steps during nervous system development \[[@B127-ijms-16-15057]\] ([Table 2](#ijms-16-15057-t002){ref-type="table"}). Binding to the corresponding BMP receptors leads to phosphorylation of the receptor-regulated transcription factors SMAD1/5/8 \[[@B128-ijms-16-15057]\]. Oligodendroglial cells express BMP4 and all three BMP receptors \[[@B129-ijms-16-15057]\], and receptor activation has been shown to inhibit oligodendroglial differentiation and promote astroglial differentiation \[[@B129-ijms-16-15057],[@B130-ijms-16-15057]\]. On the other hand, inhibited BMP signaling during experimental demyelination (cuprizone) was shown to promote mature oligodendrocyte regeneration and myelin repair \[[@B131-ijms-16-15057]\]. During demyelination increased activity of BMP signaling could also be observed in the injured rat spinal cord \[[@B132-ijms-16-15057],[@B133-ijms-16-15057]\], following local chemical demyelination \[[@B134-ijms-16-15057]\], in EAE \[[@B135-ijms-16-15057]\] as well as in MS lesions \[[@B136-ijms-16-15057]\]. As a result evaluated levels of phosphorylated SMAD1/5/8 could be detected \[[@B131-ijms-16-15057]\]. BMP-mediated phosphorylation of SMAD1 resulted in nuclear translocation and formation of a complex with the transcription factors Stat3 and p300, leading to direct activation of the GFAP promoter \[[@B137-ijms-16-15057]\]. Furthermore, TGFβ-induced phosphorylation of SMAD2/3 promoted formation of a heterotrimeric complex with SMAD4, subsequent translocation to the nucleus, and initiation of TGFβ target genes \[[@B138-ijms-16-15057]\]. In contrast, MAPKs catalyzed inhibitory phosphorylation in the SMAD1 linker region that resulted in nuclear exclusion of SMAD1, and thapsigargin-mediated increase of intracellular Ca^2+^ concentrations were found to reduce SMAD2 nuclear translocation \[[@B139-ijms-16-15057],[@B140-ijms-16-15057]\].

The genes encoding bHLH transcription factors hairy and enhancer of split-1 and -5 (Hes1 and Hes5) have been implicated as critical targets of the Notch signaling pathway, that was shown to be involved in oligodendroglial differentiation and also in T helper (Th) cell activation and differentiation \[[@B141-ijms-16-15057],[@B142-ijms-16-15057]\] ([Table 2](#ijms-16-15057-t002){ref-type="table"}). Notch receptors are expressed by oligodendroglial cells \[[@B47-ijms-16-15057],[@B143-ijms-16-15057]\] and can be activated by the Delta and Jagged1 ligands expressed by neurons and astrocytes, and they have been found to be up-regulated in experimental models such as EAE and Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) as well as in MS brains \[[@B141-ijms-16-15057],[@B144-ijms-16-15057],[@B145-ijms-16-15057],[@B146-ijms-16-15057]\]. Blockade of the Notch signaling pathway resulted in a decrease of interferon-γ, interleukin-4 or interleukin-10 producing CD4+ T cells and increased numbers of interleukin-17 producing CD4+ T cells in the spinal cords of TMEV-IDD mice resulting in a significant suppression of the disease progression \[[@B146-ijms-16-15057]\]. Within and around active MS plaques lacking remyelination, Jagged1 was expressed at high levels by hypertrophic astrocytes, whereas Notch1 and Hes5 localized to cells with an immature oligodendrocyte phenotype \[[@B144-ijms-16-15057]\]. In response to Jagged1, Notch signaling is initiated by proteolytic cleavage, driven by ADAM metalloprotease and a γ-secretase complex, and nuclear translocation of the Notch intracellular domain (NICD). In the nucleus, NICD interacts with the DNA-binding protein CSL (RBP-Jk) to activate Hes1 and Hes5 \[[@B147-ijms-16-15057]\]. Nuclear expression of Hes5 is very prominent in immature oligodendrocytes, and it has been found to prevent terminal oligodendroglial differentiation and myelination \[[@B144-ijms-16-15057],[@B148-ijms-16-15057]\]. Hes5 mediates its inhibitory effect in two ways. First, by sequestering transcriptional activators such as Ascl1/Mash1 or Sox10, and second, by directly binding to the regulatory promoter regions of myelin genes, such as MBP, thereby blocking transcription, and epigenetically modifying chromatin \[[@B148-ijms-16-15057]\]. Of note, the negative impact of Hes5 appears to be overcome in spontaneously differentiating OPCs by means of nuclear export, which has been found to depend on direct interaction with p57kip2 \[[@B55-ijms-16-15057]\] ([Figure 2](#ijms-16-15057-f002){ref-type="fig"}).
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###### 

Key transcriptional regulators.

  Molecules      Major Function in OPCs                            Role in MS/MS-Models                                                                                   References
  -------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Olig1/2        lineage determination, differentiation            cuprizone, MS lesion: activation of OPCs, remyelination                                                Arnett *et al.*, 2004 \[[@B17-ijms-16-15057]\]; Balabanov *et al.*, 2005 \[[@B101-ijms-16-15057]\]; Cheng *et al.*, 2015 \[[@B102-ijms-16-15057]\]
  Ascl1/Mash1    OPC specification, differentiation, myelination   LPC, MS lesions: oligodendrogenesis, promoted remyelination                                            Gokhan *et al.*, 2005 \[[@B109-ijms-16-15057]\]; Parras *et al.*, 2007 \[[@B106-ijms-16-15057]\]; Göttle *et al.*, 2015 \[[@B55-ijms-16-15057]\]; Sugimori *et al.*, 2008 \[[@B107-ijms-16-15057]\]; Nakatani *et al.*, 2013 \[[@B108-ijms-16-15057]\]
  GPR17 Id2/4    inhibited differentiation                         LPC, MS lesions: diminished remyelination                                                              Lecca *et al.*, 2008 \[[@B115-ijms-16-15057]\]; Chen *et al.*, 2009 \[[@B102-ijms-16-15057]\]
  SMAD           OPC specification, inhibited differentiation      cuprizone, MS lesion: diminished remyelination, astrogenesis/gliosis                                   Grinspan *et al.*, 2000 \[[@B130-ijms-16-15057]\]; Kondo *et al.*, 2004 \[[@B129-ijms-16-15057]\]; Setoguchi *et al.*, 2004 \[[@B104-ijms-16-15057]\]; Fuller *et al.*, 2007 \[[@B134-ijms-16-15057]\]; Ara *et al.*, 2008 \[[@B135-ijms-16-15057]\]; See *et al.*, 2009 \[[@B127-ijms-16-15057]\]; Sabo *et al.*, 2011 \[[@B131-ijms-16-15057]\]; Wang *et al.*, 2011 \[[@B132-ijms-16-15057]\]
  Notch Hes1/5   inhibited differentiation                         EAE, TMEV-IDD, MS lesion: activation and differentiation of T-helper cells, diminished remyelination   Jarriault *et al.*, 1998 \[[@B141-ijms-16-15057]\]; Wang *et al.*, 1998 \[[@B132-ijms-16-15057]\]; John *et al.*, 2002 \[[@B144-ijms-16-15057]\]; Hu *et al.*, 2003 \[[@B143-ijms-16-15057]\]; Liu *et al.*, 2006 \[[@B148-ijms-16-15057]\]; Elayman *et al.*, 2009 \[[@B145-ijms-16-15057]\]; Nakahara *et al.*, 2009 \[[@B47-ijms-16-15057]\]; Tsugane *et al.*, 2012 \[[@B146-ijms-16-15057]\]

Abbreviations: lysolecithin (LPC), oligodendroglial precursor cells (OPCs), Multiple sclerosis (MS), experimental autoimmune encephalomyelitits (EAE), Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD).

3.3. Posttranscriptional and Posttranslational Factors
------------------------------------------------------

Acetylation and deacetylation of histones essentially contribute to the regulation of gene expression and are catalyzed by histone acetyltransferases or histone deacetylases (HDACs), respectively. Acetylation is associated with active open chromatin and an initiated gene expression, whereas deacetylation blocks the expression of, for example, inhibitory transcription factors such as Hes5, Id2 and Id4, Tcf7l2 and Tcf4 and can thus promote myelination \[[@B117-ijms-16-15057],[@B149-ijms-16-15057],[@B150-ijms-16-15057]\]. However, Hes5 can form repressive complexes with HDACs, and insufficient recruitment of HDACs to promoter regions of such inhibitory transcriptional factors can consequently result in their continuous expression. Interestingly, this reflects the situation in cuprizone mediated demyelination of aged rodent brains, where HDAC recruitment is inefficient allowing the accumulation of transcriptional inhibitors and reduces their remyelination potential compared to younger animals \[[@B150-ijms-16-15057]\]. Of note, administration of pharmacological HDAC inhibitors (HDACi) during cuprizone treatment or after MOG~35--55~ induced EAE was able to recapitulate defective remyelination *in vivo* \[[@B150-ijms-16-15057],[@B151-ijms-16-15057],[@B152-ijms-16-15057]\]. This is in accordance with the recent finding of Ye and colleagues demonstrating that oligodendroglial differentiation requires transcriptional co-repressors HDAC1 and HDAC2. Depletion of both genes resulted in stabilization and nuclear translocation of β-catenin, which, as already discussed, prevents *Olig2* expression and thus oligodendroglial differentiation. It was therefore assumed that HDAC1 and HDAC2 compete with β-catenin for Tcf4/Lef interaction to regulate downstream genes involved in oligodendroglial differentiation \[[@B123-ijms-16-15057]\]. Studies on MS tissue samples suggested that histone deacetylation is a process rather restricted to early disease stages, the efficiency of which decreases with disease duration \[[@B153-ijms-16-15057]\].

As yet another structural protein modification process, citrullination of arginine residues is catalyzed by peptidylarginine deiminases (PADs). In normal-appearing white matter of MS patients and in a ND4 transgenic mouse model for chronic progressive primary demyelination, TNFα-dependent citrullination of histones by PAD4 was observed \[[@B154-ijms-16-15057]\]. Enhanced citrullination of MBP was shown to destabilize myelin sheaths in MS. High citrullination of histones, as a consequence of nuclear PAD4, is assumed to lead to irreversible changes in oligodendroglial chromatin organization and may contribute to oligodendroglial cell apoptosis in MS \[[@B154-ijms-16-15057]\].

The ten-eleven translocation (TET) family of methylcytosine dioxygenases catalyzes oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and promotes DNA demethylation. TET proteins have been demonstrated to regulate promoter activities in embryonic stem cells \[[@B155-ijms-16-15057]\]. Three TET family members (TET1, TET2, and TET3) were found to be critical gene expression modifiers by means of DNA-methylation during oligodendroglial differentiation, and all were characterized by unique subcellular and temporal expression patterns \[[@B156-ijms-16-15057]\]. TET1 protein levels are highest in OPCs and decline as cells mature. TET1 protein can be detected in the oligodendroglial cytoplasm, the nucleus, and the cell processes. Unlike TET1, levels of TET2 remain constant. However, during initiation of the myelination process, TET2 translocates from the cytoplasm to the nucleus, indicating that TET2 activity is specifically needed for the wrapping process. TET3 remains localized to the nucleus throughout oligodendrogenesis. Of note, *in vitro* knockdown approaches for every member of TET family enzymes resulted in up-regulation of differentiation inhibitors such as *Hes1* or *Id2* and down-regulation of *MBP* and *PLP* gene expression \[[@B156-ijms-16-15057]\]. In MS patients the expression levels of *TET2* in peripheral blood mononuclear cells was found to be significantly down-regulated and aberrant DNA hydroxymethylation resulted in decreased 5hmC levels, suggesting a relevant role in MS pathophysiology \[[@B157-ijms-16-15057]\].

3.4. Nuclear Translocation of Membrane Proteins
-----------------------------------------------

As describe above, expression of inhibitory transcription factors Hes1/5 is controlled by Notch signaling. Of note and in contrast to many membrane receptors that transmit signals to the nucleus via complex cascades, Notch receptors can also act on gene expression by translocating themselves to the nucleus. Activation of the non-canonical Notch signaling pathway by the axonal F3/contactin, for example, triggers nuclear translocation of NICD and has been demonstrated to promote both generation as well as differentiation of oligodendroglial cells \[[@B143-ijms-16-15057],[@B158-ijms-16-15057]\]. In this context, a report by Nakahara and colleagues suggests that inadequate nucleocytoplasmic transport in oligodendroglial cells affects MS progression by interfering with glial differentiation, is of particular interest \[[@B47-ijms-16-15057]\]. TAT-interacting protein 30 kDa (TIP30) is a pro-apoptotic factor expressed at elevated levels within oligodendroglial cells in MS lesions. TIP30 has been found to inhibit nuclear transport of NICD and subsequently of Notch-mediated oligodendroglial differentiation and myelination \[[@B47-ijms-16-15057],[@B159-ijms-16-15057]\]. Given that nuclear translocation of NICD is mediated by the nuclear transporter importin-β recognizing the NLS, TIP30 clearly inhibits differentiation as a direct inhibitor of importin-β \[[@B160-ijms-16-15057],[@B161-ijms-16-15057]\]. Moreover, overexpression of TIP30 was found to sequester the transcription factor Olig1 in the cytoplasm and to weaken its nuclear translocation, whereas TIP30 knockdown enhanced nuclear Olig1 localization during the initiation stage of OPC differentiation \[[@B162-ijms-16-15057]\].

The axon-derived ligand neuregulin 1 type III (NRG1) interacts with ErbB receptor tyrosine kinases expressed on oligodendroglial cells and affects their survival, maturation, and myelination \[[@B163-ijms-16-15057],[@B164-ijms-16-15057],[@B165-ijms-16-15057]\] ([Table 3](#ijms-16-15057-t003){ref-type="table"}). NRG binding provokes γ-secretase driven proteolytic cleavage and the release and nuclear translocation of ErbB4 intracellular domain (EICD), which influences target gene expression \[[@B166-ijms-16-15057]\]. Nuclear accumulation of EICD has been shown to promote MBP expression, which can be blocked by inhibition of ErbB4 or γ-secretase \[[@B164-ijms-16-15057]\]. After spinal cord injury (SCI), NRG1 signaling is decreased resulting in an inadequate ability of precursor cells to replenish oligodendrocytes \[[@B167-ijms-16-15057]\]. However, NRG1 or ErbB gene depletion were found to have no effect on remyelination following LPC-induced demyelination, whereas overexpressing NRG1 resulted in axonal hypermyelination \[[@B168-ijms-16-15057]\]. Furthermore, reduced ErbB4 expression in immune cells (total peripheral blood mononuclear cells, T cells, monocytes and B cells) of patients with relapsing remitting MS was observed, and suggests that insufficient ErbB signaling could also be associated with disease development \[[@B169-ijms-16-15057]\].

Nuclear receptors belong to a superfamily that consists of a large number of ligand-activated transcription factors \[[@B170-ijms-16-15057]\]. The superfamily encompasses two types of nuclear receptors. Type I receptors are classic steroid receptors that mediate the actions of steroid hormones such as glucocorticoids, mineralcorticoids, progestins, androgens, and estrogens. Type II receptors include thyroid hormone receptors (TRs), retinoid X receptors (RXRs), retinoic acid receptors (RARs), the receptor for 1,25-(OH)~2~ vitamin D~3~ (VDR), the peroxisome proliferator-activated receptors (PPARs), and many orphan receptors.

Upon ligand binding TRs as well as RARs exhibit nuclear localization and interact with the transcriptional machinery in the nucleus \[[@B170-ijms-16-15057],[@B171-ijms-16-15057]\]. Furthermore, these nuclear receptors bind to specific promoter regions, thereby regulating transcriptional expression of *MBP*, *PLP*, *MAG*, and *2′,3′-cyclic nucleotide 3′-phosphodiesterase* \[[@B172-ijms-16-15057]\]---hence promotes oligodendroglial cell differentiation \[[@B173-ijms-16-15057]\].

RXRs are a family of nuclear receptors previously shown to be important regulators of differentiation \[[@B174-ijms-16-15057]\] ([Table 3](#ijms-16-15057-t003){ref-type="table"}). The RXR family comprises the receptors RXRα, RXRβ, and RXRγ, which form homodimers or heterodimers with other nuclear receptors, including TRs, RARs, VDRs, and PPARs to control transcription of target genes. Interestingly, strong expression of all three RXR members was observed in lesions following CNS injury \[[@B175-ijms-16-15057]\]. During CNS remyelination RXRγ was differentially expressed in rodent oligodendroglial cells as well as in human acute and remyelinating MS lesions \[[@B176-ijms-16-15057]\]. Depending on the oligodendroglial maturation state, RXRγ can either be found in the cytoplasm of Nkx2.2-positive OPCs or in the nucleus of mature oligodendrocytes as revealed by their expression of the maturation marker adenomatous polyposis coli APC/CC1-positive. Thus localization of RXRγ in the cytoplasm may inhibit oligodendroglial differentiation, whereas nuclear localization may promote the differentiation process \[[@B176-ijms-16-15057]\]. In MS lesions, subcellular receptor localization correlated with the remyelination status as elevated nuclear RXRγ localization was observed in active remyelinating lesions compared to chronic inactive lesions \[[@B176-ijms-16-15057]\].

The PPARs function as transcription factors to regulate target genes that are involved in lipid metabolism, and they have been shown to play a significant role in oligodendroglial differentiation \[[@B177-ijms-16-15057],[@B178-ijms-16-15057],[@B179-ijms-16-15057]\] ([Table 3](#ijms-16-15057-t003){ref-type="table"}). Upon ligand binding PPARs form heterodimers with RXR receptors. They can also translocate into the nucleus and interact with specific PPAR response elements (PPREs) in the promoter region of PPAR-target genes, resulting in enhanced MBP transcript levels as well as an increased numbers of O4-, O1-, and MBP-positive cells \[[@B179-ijms-16-15057]\]. After spinal cord injury the number of PPAR+ oligodendroglial cells were found to be increased and to correlate in time and location with regions featuring robust oligodendrogenesis \[[@B180-ijms-16-15057]\]. Furthermore, elevated expression of PPARγ has been observed during EAE in mice and PPARγ agonists were shown to ameliorate the disease course by inhibiting the expansion of encephalitogenic T cells \[[@B181-ijms-16-15057]\]. Moreover, elevated levels of PPARγ have been observed in the cerebrospinal fluid of patients with MS \[[@B182-ijms-16-15057]\]. The thromboxane A2 (TXA2) receptor (TPR) was found to be expressed in the developing rat brain during myelination, and expression levels increased during oligodendrocyte maturation \[[@B183-ijms-16-15057]\]. During differentiation, TPR translocates from the cytoplasm in OPCs to the nucleus in oligodendrocytes, and receptor activation has been shown to result in CREB phosphorylation and to enhance MBP promoter activity \[[@B184-ijms-16-15057]\].
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###### 

Nuclear translocation of membrane proteins.

  Molecules   Major Function in OPCs                   Role in MS/MS-Models                                     References
  ----------- ---------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NRG         survival, differentiation, myelination   LPC, MS lesions: oligodendrogenesis, immune cells        Barres *et al.*, 1999 \[[@B165-ijms-16-15057]\]; Fernandez *et al.*, 2000 \[[@B163-ijms-16-15057]\]; Lai *et al.*, 2004 \[[@B164-ijms-16-15057]\]; Brinkmann *et al.*, 2008 \[[@B168-ijms-16-15057]\]; Tynyakov-Samra *et al.*, 2011 \[[@B169-ijms-16-15057]\]; Gauthier *et al.*, 2013 \[[@B167-ijms-16-15057]\]
  RXRs        differentiation                          LPC, MS lesions: remyelination                           Schrage *et al.*, 2006 \[[@B175-ijms-16-15057]\]; Huang *et al.*, 2011 \[[@B176-ijms-16-15057]\]
  PPARs       differentiation                          SCI, EAE, MS lesions: oligodendrogenesis, immune cells   Saluja 2001 *et al.*, \[[@B177-ijms-16-15057]\]; Woods *et al.*, 2003 \[[@B178-ijms-16-15057]\]; Almad *et al.*, 2010 \[[@B180-ijms-16-15057]\]; Bernardo *et al.*, 2013 \[[@B179-ijms-16-15057]\]; Szalardy *et al.*, 2013 \[[@B182-ijms-16-15057]\]; Unoda *et al.*, 2013 \[[@B181-ijms-16-15057]\]

Abbreviation: lysolecithin (LPC), Multiple Sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), spinal cord injury (SCI).

3.5. RNA Transport {#sec3dot5-ijms-16-15057}
------------------

Apart from a number of proteins for which the subcellular localizations is arranged during oligodendrogenesis, strong evidence also exists for the subcellular transport and distribution of selected RNA molecules. Notably, mRNAs for myelin proteins such as MBP are transported from the nucleus to terminal processes of oligodendroglial cells, where they are locally translated at the site of developing myelin sheaths \[[@B185-ijms-16-15057]\]. In oligodendroglial cells, specific mRNA molecules are transported in RNA-protein complexes termed RNA granules that contain several essential molecules of the translational machinery including aminoacyl-tRNA synthetases, elongation factors and ribosomes \[[@B186-ijms-16-15057]\]. RNA granules are carried along microtubules by the activity of kinesin and dynein motor proteins \[[@B187-ijms-16-15057]\]. Before RNA granules reach their destination they are in a translationally silenced state and local translation becomes initiated upon specific signals \[[@B188-ijms-16-15057],[@B189-ijms-16-15057]\]. Of note, in neurons retrograde transport and the activity of dynein binding proteins LIS1 and NDEL crucial for axonal transport are dependent on the activity of CDK5 \[[@B58-ijms-16-15057]\]. Hence, decreased oligodendroglial maturation in the absence of CDK5 has been proposed to result from perturbed mRNA transport \[[@B57-ijms-16-15057]\].

RNA granule formation, cargo selection, and cytoplasmic transport are tightly controlled by RNA-binding proteins referred to as the trans*-*acting factors heterogeneous nuclear ribonucleoproteins, including hnRNPA2, -A3 and quaking (QKI) \[[@B190-ijms-16-15057],[@B191-ijms-16-15057]\]. Mutations in hnRNPs are thought to contribute to the pathogenesis of MS because some patients exhibit a single nucleotide variant in the hnRNPA1-encoding sequence leading to protein mislocalization and colocalization with stress granules and causing cellular apoptosis \[[@B192-ijms-16-15057],[@B193-ijms-16-15057]\]. Stress granules (SGs) are aggregates of stalled translational preinitiation complexes that accumulate during stress. mRNAs in SGs are not translated as they do not contain 60S ribosomal subunits \[[@B194-ijms-16-15057],[@B195-ijms-16-15057]\]. Thus, it is assumed that SGs store mRNA and ensure its sorting between translation and degradation \[[@B195-ijms-16-15057]\]. The alternative splice isoform QKI-6 may be a component of SGs in oligodendroglial cells \[[@B191-ijms-16-15057]\], and QKI-7 has been demonstrated to induce oligodendroglial apoptosis, whereas heterodimerization of QKI isoforms and subsequent nuclear translocation of QKI-7 can suppress apoptotic cell death \[[@B196-ijms-16-15057]\].

However, MBP protein variants, resulting from different mRNA splice variants, have been shown to be differently distributed within oligodendroglial cells, depending on which isoforms are encoded by exons I-VII \[[@B197-ijms-16-15057]\]. It was speculated that exon II MBP proteins may contain an NLS sequence and become actively transported through the NPC into the oligodendroglial nucleus \[[@B198-ijms-16-15057]\]. Of note, nuclear MBP protein accumulation has been shown to influence cellular proliferation by elevating phosphorylation of ERK1/2 and Akt1 signaling proteins, indicating that secondary functions besides myelin sheath constitution and electrical isolation are encoded \[[@B197-ijms-16-15057],[@B199-ijms-16-15057],[@B200-ijms-16-15057]\].

Finally, lamins-the structural components of the filamentous protein meshwork essential to inner nuclear membrane structure-are also functionally engaged in maturation processes. Overexpression of lamin B1 leads to a disturbance of inner nuclear membrane proteins and of chromatin organization, mislocalization of NPCs, and impaired nuclear pore transport \[[@B201-ijms-16-15057],[@B202-ijms-16-15057]\]. As a consequence, premature arrest of oligodendroglial differentiation, due to reduced myelin transcription and misguided myelin proteins, is observed \[[@B202-ijms-16-15057]\]. Interestingly, microRNA (miR)-dependent regulation, namely by miR-23, can contribute to this process \[[@B202-ijms-16-15057]\].

4. Conclusions
==============

Since deregulated nucleocytoplasmic transport and the subsequent aberrant intracellular distribution of proteins appears to be critically involved in oligodendroglial differentiation failure and in myelin repair deficits ([Figure 3](#ijms-16-15057-f003){ref-type="fig"}), the identification of rate-limiting factors, either for export and/or import activities, might help to identify new target structures for future pharmacological remyelination therapies. In light of the growing number of immunomodulatory treatments approved for treating MS and the fact that no treatment options currently exist for damage repair, interest in the development of such therapies is increasing. It remains to be shown whether currently known proteins/(protein-complexes), as described here, are suitable targets for such strategies or whether superior (master) regulators need to be identified. Of note, recent studies in EAE mice revealed that oral administration of reversible CRM1 inhibitors could significantly attenuate disease progression \[[@B203-ijms-16-15057]\]. Among effects on the immune cell compartment demyelinated axons appeared to be preserved by this treatment indicating that nucleocytoplasmic transport is also a critical process for neuroprotection. In light of this new data, it remains to be shown to what extent axonal regeneration/preservation and myelin repair, the two major deficits in the injured and diseased CNS, can simultaneously be promoted by pharmacological modulators of importins and exportins.

![Summary of intracellular translocation directions of selected key proteins involved in transcriptional regulation, cell cycle control and transmission of cell surface signals revealed to be important for differentiation of immature oligodendroglial cells. (1) Nuclear import of Notch intracellular domain (NICD) was shown to have a different impact on the differentiation process depending on the nature of Notch ligands (Jagged1, F3/contactin); (2) The Mash1 protein is not exported from the nucleus; however, its inhibitory binding partner p57kip2 is actively translocated during the differentiation process thereby allowing Mash1 dependent transactivation of target genes to occur.](ijms-16-15057-g003){#ijms-16-15057-f003}
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